Immunological studies and in vitro schistosomicide action of new imidazolidine derivatives

• Published in: Journal of Venomous Animals and Toxins including Tropical Diseases
• Main Authors: Neves JKAL, Sarinho S, de Melo CML, Pereira VRA, de Lima MCA, Pitta IR, Albuquerque MCPA, Galdino SL
• Format: Article in Journal/Newspaper
• Language: English
• Published: SciELO 2011
• Subjects: Schistosoma mansoni; in vitro; imidazolidines; Arctic medicine. Tropical medicine; RC955-962; Toxicology. Poisons; RA1190-1270; Zoology; QL1-991; Arctic
• Online Access: https://doi.org/10.1590/S1678-91992011000300007; https://doaj.org/article/d47146f2220645099d087a6623984741

Schistosomiasis is a major public health problem with 207 million people infected and more than 779 million at risk. The drug of choice for treating schistosomiasis is praziquantel (PZQ); however, it is inefficient against immature forms of schistosomes. The aim of this study was to test new imidazolidine derivatives LPSF/PT09 and LPSF/PT10 against adult Schistosoma mansoni worms. IC50, cytotoxicity, immune response and cell viability assays were also available for these imidazolidines. Different concentrations of imidazolidine, from 32 to 320 ¼M, promoted motor abnormalities in breeding and unpaired worms, and death in 24 hours at higher concentrations. Although LPSF/PT09 and LPSF/PT10 did not affect IFN-³ and IL-10 production, they induced nitric oxide production and showed a similar behavior to praziquantel on cell death test. Thus, these new imidazolidine derivatives should undergo further study to develop schistosomiasis drugs.